Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

European Heart Journal

Volumn 33, Issue 23, 2012, Pages 2970-2979

  Sever, Peter S ^a   Chang, Choon L ^a   Prescott, Margaret F ^b   Gupta, Ajay ^a   Poulter, Neil R ^a   Whitehouse, Andrew ^a   Scanlon, Michael ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Cardiovascular outcomes; Hypertension; Plasma renin activity; Renal

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PERINDOPRIL; PLACEBO;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE TITRATION; ETHNICITY; FEMALE; GROUPS BY AGE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KIDNEY DISEASES; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RENIN; STROKE; TREATMENT OUTCOME;

EID: 84870799049     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs241     Document Type: Article

References (26)

1. Ferrario CM. Role of angiotensin II in cardiovascular disease-therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7:3-14.
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(Suppl.):3A-10A.
3. Kwoh C, Shannon MB, Miner JH, Shaw A. Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 2006;1:349-374.
4. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972;286:441-449.
5. Alderman MH, Madhavan S, Ooi WL, Hillel Cohen MPH, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-1104.
6. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993;329:616-619.
7. Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007;28:2644-2652.
8. Meade T. Plasma renin and the incidence of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010;11:91-98.
9. Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson JL. Relation of evaluated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010;106: 764-769.
10. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Cardiac Fail 2010;16:964-970.
11. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011;32:2135-2142.
12. Muhlestein J. Elevated plasma renin activity (PRA) is associated with adverse renal outcomes in patients with coronary artery disease. Abstract presented at the World Congress of Nephrology 2011, Vancouver, BC, Canada.
13. Sever PS, Dahlö f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001;6:1139-1147.
14. Dahlö f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366: 895-906.
15. Sever PS, Dahlö f B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
16. Menard J, Catt KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology 1972;90:422-443.
17. Sever PS, Poulter NP, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2012;33:486-494.
18. Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001;10: 247-255.
19. Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar-Zadeh K. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California Cohort. J Hypertens 2011;29:2226-2235.
20. Deinum J, Ronn B, Mathiesen E, Derkx FHM, Hop WC, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-1010.
21. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033.
22. Azizi M, Menard J. Measurement of plasma renin: a critical review of methodology. J Renin Angiotensin Aldosterone Syst 2010;11:89-90.
23. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW. Prediction of myocardial infarction by N-Terminal-Pro-B-Type natriuretric peptide, c-reactive protein, and renin in subjects with cerebrovascular disease. Circulation 2005;112:110-116.
24. Gupta AK, Prieto-Merino D, Dahlof B, Sever PS, Poulter NR; on behalf of the ASCOT Investigators. Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. Diabetic Med 2011;28:941-947.
25. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR; on behalf of the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011;32: 2525-2532.
26. Woodward M. Epidemiology: Study Design and Data Analysis. Chapman & Hall/CRC, USA; 2004.